{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:41Z","timestamp":1790875901908,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Although the treatment of peripheral T-cell lymphoma (PTCL) has undergone advancements during the past several years, the response rate and long-term effects with respect to patients with PTCL remain unsatisfactory\u2014particularly for relapsed or refractory (R\/R) patients. This phase II trial was designed to explore the efficacy and safety of an all-oral regimen of chidamide plus prednisone, cyclophosphamide, and thalidomide (CPCT) for R\/R PTCL patients who could not tolerate the standard chemotherapy for a variety of reasons.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a multicenter phase II clinical trial in which we combined chidamide (30 mg twice weekly) with prednisone (20 mg daily after breakfast), cyclophosphamide (50 mg daily after lunch), and thalidomide (100 mg daily at bedtime) (the CPCT regimen) for a total of fewer than 12 cycles as an induction-combined treatment period, and then applied chidamide as single-drug maintenance. Forty-five patients were ultimately enrolled from August 2016 to April 2021 with respect to Chinese patients at nine centers. Our primary objective was to assess the overall response rate (ORR) after the treatment with CPCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 45 enrolled patients, the optimal ORR and complete response (CR)\/CR unconfirmed (CRu) were 71.1% (32\/45) and 28.9% (13\/45), respectively, and after a median follow-up period of 56 months, the median progression-free survival (PFS) and overall survival (OS) were 8.5 months and 17.2 months, respectively. The five-year PFS and OS rates were 21.2% (95% confidence interval [CI], 7.9\u201334.5%) and 43.8% (95% CI, 28.3\u201359.3%), respectively. The most common adverse event was neutropenia (20\/45, 44.4%), but we observed no treatment-related death.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The all-oral CPCT regimen was an effective and safe regimen for R\/R PTCL patients who could not tolerate standard chemotherapy for various reasons.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT02879526.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002836","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:30:27Z","timestamp":1697423427000},"page":"1576-1582","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial"],"prefix":"10.1097","volume":"137","author":[{"given":"Jinhua","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, Sichuan 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyao","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu 210008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu 210009, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of lymphoid neoplasms in China: Analysis of 4, 638 cases according to the World Health Organization classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.14473","article-title":"How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: Current practice and a glimpse into the future","volume":"176","author":"Schmitz","year":"2017","journal-title":"Br J Haematol"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"R5-20250602","first-page":"623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: Low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.26499","article-title":"Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial","volume":"97","author":"Wang","year":"2022","journal-title":"Am J Hematol"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-016-0267-0","article-title":"Therapeutic options in peripheral T cell lymphoma","volume":"9","author":"Zhang","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Coiffier","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-20250602","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15384047.2016.1219820","article-title":"The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines","volume":"17","author":"Cosenza","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): Report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: An open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/cas.14906","article-title":"Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma","volume":"112","author":"Kawai","year":"2021","journal-title":"Cancer Sci"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"106705","DOI":"10.1016\/j.leukres.2021.106705","article-title":"Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma","volume":"111","author":"Wang","year":"2021","journal-title":"Leuk Res"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.16428","article-title":"The new biology of PTCL-NOS and AITL: Current status and future clinical impact","volume":"189","author":"Timmins","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:02:13Z","timestamp":1748890933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,10]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002836","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,10]]},"assertion":[{"value":"2023-07-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}